Intellia Says Sickle Cell Therapy Still ‘Wide Open’ As Novartis And Others Exit

Graphite Bio And Sangamo Also Dropping Out

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.